Efficacy of three innovative bacterin vaccines against experimental infection with Mycoplasma hyopneumoniae

• DOI: 10.1186/s13567-019-0709-0
• Publication Date: 2019-11-08T15:21:02Z
• Authors: Anneleen Margueri...; Gaël Auray; Filip Boyen; Alexandra Schoos; Annelies Michiels; Obdulio García-Ni...; Güliz Tuba Barut; Christophe Barnie...; Virginie Jakob; Nicolas Collin; Bert Devriendt; Artur Summerfield; Freddy Haesebrouck; Dominiek Maes
• Keywords: Mycoplasma hyopneumoniae

New vaccine formulations that include novel strains of Mycoplasma hyopneumoniae and innovative adjuvants designed to induce cellular immunity could improve efficacy against this pathogen. The aim experimental study was assess the three bacterin based on M. field strain F7.2C which were able immunity. included a cationic liposome formulation with Mincle receptor ligand trehalose 6,6-dibehenate (Lipo_DDA:TDB), squalene-in-water emulsion Toll-like (TLR) ligands targeting TLR1/2, TLR7/8 TLR9 (SWE_TLR), poly(lactic-co-glycolic acid) micro-particle same TLR (PLGA_TLR). Four groups 12 hyopneumoniae-free piglets primo- (day (D) 0; 39 days age) booster vaccinated (D14) intramuscularly either one or PBS. pigs endotracheally inoculated highly low virulent D28 D29, respectively, euthanized D56. main parameters were: respiratory disease score (RDS; daily), macroscopic lung lesion (D56) log copies DNA determined qPCR bronchoalveolar lavage (BAL) fluid (D42, D56). All reduce clinical symptoms, lesions load in lung, SWE_TLR being most effective (RDSD28-D56 -61.90%, -88.38%, BAL (D42) -67.28%). Further experiments raised under conditions are needed confirm these results effect vaccines performance parameters.